Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma subtype and is clinically aggressive. To identify genetic susceptibility loci for DLBCL, we conducted a meta-analysis of 3 new genome-wide association studies (GWAS) and 1 previous scan, totaling 3,857 cases and 7,666 controls of European ancestry, with additional genotyping of 9 promising SNPs in 1,359 cases and 4,557 controls. In our multi-stage analysis, five independent SNPs in four loci achieved genome-wide significance marked by rs116446171 at 6p25.3 (EXOC2; P = 2.33 × 10 −21 ), rs2523607 at 6p21.33 (HLA-B; P = 2.40 × 10 −10 ), rs79480871 at 2p23.3 (NCOA1; P = 4.23 × 10 −8 ) and two independent SNPs, rs13255292 and rs4733601, at 8q24.21 (PVT1; P = 9.98 × 10 −13 and 3.63 × 10 −11 , respectively). These data provide substantial new evidence for genetic susceptibility to this B cell malignancy and point to pathways involved in immune recognition and immune function in the pathogenesis of DLBCL. DLBCL, the most common subtype of non-Hodgkin lymphoma (NHL) 1 , has an aggressive clinical course 2 . The risk of DLBCL is higher in individuals with a family history of NHL (odds ratio (OR) = 1.4, 95% confidence interval (CI) = 1.1-2.0) 3 , supporting a genetic contribution. Also, relatives of individuals with DLBCL are at elevated risk for both DLBCL (relative risk (RR) = 9.8, 95% CI = 3.1-31) and Hodgkin lymphoma (RR = 2.0, 95% CI = 1.05-4.0) but not indolent lymphomas 4 . In candidate gene studies investigating susceptibility to DLBCL, only one locus, the LTA 252A>G (rs909253)/TNF -308G>A (rs1800629) haplotype on chromosome 6p21, reached genome-wide significance (P = 2.9 × 10 −8 ) 5 . In small GWAS of all NHL subtypes combined, no conclusive loci for NHL or DLBCL were identified in individuals of European background [6] [7] [8] [9] , whereas a recent study conducted in East Asians identified an associated locus at 3q27 (ref. 10) .
To discover new DLBCL susceptibility loci, in stage 1, we genotyped 2,878 DLBCL cases and 2,854 controls of European ancestry from 22 studies using the Illumina OmniExpress BeadChip (Online Methods, Supplementary Fig. 1 and Supplementary Table 1) . A total of 5,346 (93.3%) samples and 611,844 SNPs successfully passed rigorous quality control criteria (Online Methods and Supplementary Table 2 ). To augment the number of controls, genotype data from 3,536 cancer-free controls previously analyzed with the Omni2.5 SNP microarray were folded into the analytical build 11 , resulting in a total of 2,661 cases and 6,221 controls for the stage 1 GWAS analysis (Supplementary Table 2 ).
In stage 1, with adjustment for sex, age and four eigenvectors (Online Methods), we observed an enrichment of SNPs with smaller P values in comparison to the null distribution of no association in the quantilequantile plot, with a λ value (genomic inflation factor) of 1.016 ( Supplementary Fig. 2 ). Two SNPs exceeded the threshold for genomewide significance (P < 5 × 10 −8 ), and 20 SNPs showed highly suggestive associations (P < 5 × 10 −7 ) (Supplementary Fig. 3 ). All but one SNP mapped to the human leukocyte antigen (HLA) region of chromosome 6 (29. Table 4 ). In meta-analysis of all genotyped and high-quality imputed SNPs from stages 1 and 2 (n = 8,363,971), we identified 19 SNPs at genome-wide significance (P < 5 × 10 −8 ) (Supplementary Table 5 ) and 134 SNPs at a suggestive level of significance (P < 5 × 10 −7 ) (Supplementary Table 6 ); 123 of the 153 total SNPs mapped to the HLA region on chromosome 6. On the basis of these results, we selected and successfully designed TaqMan primers for 8 promising SNPs (P < 5 × 10 −6 ) outside the HLA region and 1 SNP from the HLA region for stage 3 de novo genotyping in an additional 1,359 DLBCL cases and 4,557 controls (Online Methods and Supplementary Tables 1 and 3) .
In a meta-analysis of all three stages (Supplementary Table 7) , we identified four non-HLA SNPs in three newly associated loci at 6p25.3 (rs116446171, P = 2.33 × 10 −21 ) near EXOC2, 8q24.21 (rs13255292, P = 9.98 × 10 −13 ; rs4733601, P = 3.63 × 10 −11 ) near PVT1 and MYC, and 2p23.3 (rs79480871, P = 4.23 × 10 −8 ) near NCOA1 (Fig. 1a-c and Table 1 ). The two 8q24.21 SNPs displayed minimal linkage disequilibrium (LD; r 2 = 0.03 in the 1000 Genomes Project CEU population of Northern and Western European ancestry). Furthermore, in conditional analysis, both rs13255292 (conditional OR = 1.22; P = 1.39 × 10 −12 ) and rs4733601 (conditional OR = 1.18; P = 2.84 × 10 −10 ) remained genome-wide significant; together, these data support the presence of two independent SNPs associated with DLBCL at 8q24.21. We also observed two suggestive SNPs (P < 5 × 10 −7 ) (Supplementary Table 8 ), one at 5q31.3 (rs79464052, P = 5.57 × 10 −8 ) in ARAP3 (Supplementary Fig. 4 ) and one at 3q13.33 (rs2681416), although the latter SNP did not replicate in stage 2 or 3.
l e t t e r s
Within the HLA region, rs2523607 (P = 3.35 × 10 −9 ) was carried forward for replication in stage 3. This SNP, located at 6p21 in HLA-B, reached combined P = 2.40 × 10 −10 in the meta-analysis of all three stages ( Fig. 1d and Table 1 ). To further evaluate the association of HLA variants with DLBCL risk, we imputed classical HLA alleles at six loci (HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1 and HLA-DQB1) in the four GWAS data sets from stages 1 and 2 and conducted a meta-analysis (Online Methods). The imputation accuracy for HLA types was high (>95.2%) when imputed types were compared to the results from HLA sequencing (four-digit resolution) previously performed on a subset of the National Cancer Institute (NCI) samples 14 scanned as part of this study in stage 1 (Online Methods). Of all the SNPs and classical HLA alleles tested across the major histocompatibility complex (MHC), only the rs2523607 SNP (OR = 1.34; P = 3.3 × 10 −9 in stages 1 and 2) and the HLA-B*08:01 classical allele (OR = 1.30; P = 3.16 × 10 −8 in stages 1 and 2) reached genome-wide significance (Supplementary Table 9 ). These markers were in very high LD (r 2 = 0.91), and, after adjusting for the npg l e t t e r s effect of HLA-B*08:01, the association of rs2523607 was greatly weakened (P = 5.5 × 10 −3 ).
To gain additional insight into potential biological mechanisms, we performed expression quantitative trait locus (eQTL) analyses in two data sets consisting of lymphoblastoid cell lines (Online Methods). In one of the data sets, significant associations were observed for rs116446171 with HIST1H3F and for rs2523607 with HCG27 (Supplementary Table 10 ), whereas in the other data set significant associations (false discovery rate (FDR) < 0.05) were observed for rs2523607 (using rs3130923 as a proxy, r 2 = 0.94) with LY6G6E, FLOT1 and RNF5 (Supplementary Table 11 ); no associations were observed for the other DLBCL-associated loci.
To explore plausible mechanisms for the noncoding variants identified in our GWAS, the sentinel SNPs and those in high LD (r 2 ≥ 0.8) in European-ancestry individuals in the 1000 Genomes Project were analyzed using HaploReg v2 (ref. 15) (Online Methods and Supplementary Table 12 ). In addition, B cell-specific chromatin dynamics were assessed in a lymphoblastoid cell line (GM12878) with ChroMoS 16 , which uses the precomputed chromatin state data for nine cell lines (including GM12878) 17 . Of the 173 SNPs queried, 61 had information for GM12878 cells ( Supplementary Fig. 5 ); 3 SNPs were identified as active or weak promoters only in GM12878 cells, whereas 22 SNPs were identified as strong or weak enhancers in GM12878 cells. In the other eight cell lines, these regions were mostly defined as neutral, weakly transcribed or Polycomb repressed. These results suggest that some of our SNPs are within regions of active chromatin predominantly within B cells and have a role in the B cell cis-regulatory network. These results are consistent with growing evidence that disease-associated variants from GWAS are more likely to map to active chromatin sites than neutral sites, as was shown recently for systemic lupus erythematosus 17 . HaploReg showed that the majority of DLBCL-related SNPs were present in regions of DNase I hypersensitivity common across multiple cell lines (for example, rs116446171, rs2523607, rs13255292 and rs4733601 near EXOC2, HLA-B, PVT1 or 7SK, respectively), whereas rs147193201 was in a DNase I hypersensitivity site specific to B cells. The preponderance of DNase I hypersensitivity sites at associated SNPs points to the existence of motifs, such as enhancers, silencers, promoters, insulators and other control elements of gene regulation. The proteins bound at these sites are known transcription factors such as nuclear factor (NF)-κB, MYC and GATA2 or factors that regulate transcription such as POL24H8, USF1 or POL2. These suggested mechanisms of action will require laboratory follow-up.
The susceptibility locus at 6p25.3 (rs116446171) maps near a plausible DLBCL candidate gene, EXOC2 (encoding exocyst complex component 2), whose gene product forms part of a large multiprotein complex responsible for vesicle trafficking and maintenance and the intercellular transfer of viral proteins and virions 18 . The EXOC2 protein functions at the interface between host defense and cell death regulation 19 . EXOC2 interacts with Ral proteins, and the Ral-exocyst regulatory node has a crucial role in the maintenance of epithelial cell polarity, cell motility and cytokinesis 20, 21 and in proliferation and metastasis 20, 22 . It is notable that IRF4 is centromeric to EXOC2, and genetic variation in this region has been linked with chronic lymphocytic leukemia (CLL) risk 23, 24 and nominally with DLBCL risk 25 . However, rs116446171 was not in LD with rs872071, the GWAS-identified SNP for CLL risk in IRF4 (ref. 23 ).
The two 8q24.21 variants (Fig. 1b) , rs13255292 and rs4736601 positioned at 129.07 Mb and 129.26 Mb on chromosome 8, respectively, are approximately 1 Mb telomeric to the 8q24 region that is linked with multiple cancers 26 , including CLL 27 . Both variants are in close proximity to PVT1, which is a noncoding RNA implicated in MYC activation. Notably, a variant at 8q24.21 (rs2019960) has been linked to Hodgkin lymphoma 28 , but the pairwise r 2 values of this SNP with both of our SNPs were low (r 2 < 0.02 for both). The close proximity of PVT1 and the MYC oncogene, which is known to be deregulated in Burkitt lymphoma 29, 30 and some DLBCLs 31, 32 , suggests that germline variation in this region could also contribute to DLBCL risk.
The susceptibility locus at 2p23.3 (rs79480871) maps near NCOA1, encoding nuclear receptor coactivator 1, and ITSN2, encoding intersectin 2. The former gene encodes a protein that acts as a transcriptional coactivator for steroid and nuclear hormone receptors and is a member of 33 , and the latter gene encodes a protein that is a member of a family of proteins involved in clathrin-mediated endocytosis 34 and might also augment the induction of T cell receptor endocytosis 35 39 . Classical alleles for other HLA loci might also be involved (including those on the 8.1 haplotype), but larger sample sizes will be required to evaluate this possibility.
Our study represents the largest DLBCL GWAS in individuals of European descent. We did not observe a notable signal for a locus previously reported for DLBCL at 3q27 in East Asians 10 , rs6773854 (reported with OR = 1.47 and P = 1.14 × 10 −11 ), identified with a discovery set of 253 B cell NHL cases (148 DLBCLs). Although our current study had a similar minor allele frequency (MAF) for this SNP of 0.22 among controls, we observed an OR of 1.06 and a P value of 0.81 for association (Supplementary Table 13 ), suggesting that the reported marker might not be correlated with the functional susceptibility allele in individuals of European ancestry. Of the two suggestive loci (P < 5 × 10 −7 ) reported in the literature 8,40 , we did not observe an association for rs751837 with DLBCL (OR = 0.97; P = 0.46), identified in a small Japanese GWAS (OR = 3.51; P = 3.3 × 10 −7 ) 40 , but we did observe a consistent albeit attenuated association for rs10484561 (OR = 1.18; P = 1.5 × 10 −4 ), which was initially reported for a subset of the studies in stage 1 (OR = 1.36; P = 1.46 × 10 −7 ) 8 . Previously, an InterLymph study of ~1,800 DLBCLs and ~6,500 controls reported a strong signal for a dinucleotide haplotype in the LTA-TNF locus (LTA 252A>G (rs909253)/TNF -308G>A (rs1800629)) at 6p21.3 (OR = 1.31; P = 2.9 × 10 −8 ) 5 . Although nearly all of the cases from the previous publication were included in our current GWAS, the signal we observed overall was weaker (OR = 1.15; P = 8.5 × 10 −4 ). The attenuation was not explained by study design (case-control, cohort) or adjustment for population substructure (data not shown) but could be due to population sampling differences, heterogeneity or chance.
To explore the heritability of DLBCL, we estimated the contribution of all common SNPs to the variance explained by fitting all genotyped autosomal SNPs simultaneously using the method proposed by Yang et al. 41 in the stage 1 data set. We estimated that common SNPs, including but not limited to the loci discovered in this study, explained approximately 16% of the variance in DLBCL risk overall.
In summary, our findings represent an important step in defining the contribution of common genetic variants to risk for DLBCL. Our findings are notable because we have newly defined associations of several regions with susceptibility to DLBCL, and these regions harbor plausible candidate genes for further investigation. Further studies are required to discover additional common susceptibility loci as well as functional analyses that can explain the biological underpinnings of these new susceptibility loci.
URLs. HapMap, http://www.hapmap.org/.
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Stage 1: DLBCL GWAS. As part of a larger initiative, we conducted a GWAS of DLBCL using cases and controls of European descent from 22 studies of NHL (Supplementary Table 1) , including 9 prospective cohort studies, 8 population-based case-control studies and 5 clinic-or hospital-based case-control studies. All studies were approved by their respective institutional review boards, and informed consent was obtained for all participants. Cases were ascertained from cancer registries, clinics or hospitals, or through self-report verified by medical and pathology reports. To determine NHL subtype, phenotype data for all NHL cases were harmonized to the hierarchical classification proposed by the InterLymph Pathology Working Group 42, 43 based on World Health Organization (WHO) classification 44 .
All DLBCL cases with sufficient DNA (n = 2,878) and a subset of controls (n = 2,854) frequency matched by age, sex and study to the entire group of NHL cases, along with 4% quality control duplicates, were genotyped on the Illumina OmniExpress BeadChip at the NCI Cancer Genomic Research Laboratory (CGR). Genotypes were called using Illumina GenomeStudio software, and quality control duplicates showed >99% concordance. Monomorphic SNPs and SNPs with a call rate of <95% were excluded. Samples with a call rate of ≤93%, a mean heterozygosity of <0.25 or >0.33 on the basis of the autosomal SNPs or sex discordance (>5% heterozygosity on the X chromosome for males and <20% heterozygosity on the X chromosome for females) were excluded. Furthermore, unexpected duplicates (>99.9% concordance) and first-degree relatives, defined as having identity-by-descent (IBD) sharing of Pi-hat > 0.40, were excluded. Ancestry was assessed using the Genotyping Library and Utilities (GLU) struct.admix module based on the method by Pritchard et al. 45 , and participants with <80% European ancestry were excluded ( Supplementary  Fig. 6 ). After exclusions, 2,661 (92.5%) cases and 2,685 (94.1%) controls remained (Supplementary Table 2 ). Genotype data previously generated on the Illumina Omni2.5 BeadChip from an additional 3,536 controls from 3 of the studies (ATBC, CPSII and PLCO) were also included 11 , resulting in a total of 2,661 cases and 6,221 controls for the stage 1 analysis. Of these additional 3,536 controls, 703 (~235 from each study) were selected to be representative of their cohort and cancer-free individuals 11 , whereas the remainder were cancerfree controls from an unpublished study of prostate cancer in PLCO. SNPs with a call rate of <95%, with a Hardy-Weinberg equilibrium P value of <1 × 10 −6 or with a MAF of <1% were excluded from analysis, leaving 611,844 SNPs for analysis (Supplementary Table 4) . To evaluate population substructure, a principal-components analysis (PCA) was performed using the GLU, version 1.0, struct.pca module, which is similar to EIGENSTRAT 46 . Plots of the first five principal components are shown in Supplementary Figure 7 . Association testing was conducted assuming a log-additive genetic model, adjusting for age, sex and four significant (P < 0.05) principal components. All data analysis and management was conducted using GLU.
Stage 2: in silico analysis of three independent DLBCL GWAS. Three independent DLBCL GWAS provided genotyping data for a meta-analysis (Supplementary Table 1) , which included data generated with the following commercial SNP microarrays: Illumina HumanHap660W for Mayo (393 DLBCL cases and 172 controls), HumanCNV370-Duo for UCSF 7 (254 DLBCL cases and 748 controls) and HumanHap610K for GELA (549 cases). In all studies, subjects with a genotyping call rate of <95%, duplicates, related individuals and SNPs with a call rate of <95% were removed before imputation (Supplementary Table 4) . The GELA study was conducted on cases only; controls were drawn from a pool of 928 individuals from the French component of the EPIC cohort, who were previously scanned on Illumina HumanHap660W or HumanHap610K 47, 48 . We subsequently chose a subset of 525 individuals with matched ancestry as determined by PCA. In total, there were 1,196 cases and 1,445 controls in stage 2.
Imputation was conducted separately for each study in stages 1 and 2 using IMPUTE2 (ref. 13 ) and the 1000 Genomes Project version 3 (ref. 12) . The imputation analysis was restricted to common SNPs (MAF cutoff of >0.01 with an imputation accuracy INFO score of >0.3).
Association testing was conducted for each study using SNPTEST version 2, adjusting for age, sex and any significant principal components. We evaluated the top ten eigenvectors for the GELA, Mayo and UCSF studies in each baseline risk model, adjusting for both age and sex. On the basis of the significance level (P < 0.05) of the regression coefficient for eigenvectors, we chose to adjust for three eigenvectors (EV1, EV7 and EV8) for GELA in the final association model, whereas no eigenvectors met the criteria for adjustment for either the Mayo or UCSF study.
All meta-analyses were performed using the fixed-effects inverse variance method based on the β estimates and standard errors from each study. Table 7 ) were taken forward for de novo replication in an additional 1,359 cases and 4,557 controls from 4 studies (Supplementary Table 1) , except for rs2523607, which was not genotyped in any of the studies (NCI replication). Genotyping was conducted using custom TaqMan genotyping assays (Applied Biosystems) at the NCI CGR. Each assay was optimized and validated with 270 HapMap samples and additional CEPH samples (SNP500Cancer), and these samples were used as genotyping controls for clustering and reproducibility analysis. All validated assays had 99% or higher concordance with HapMap data, and completion with control DNA was >97%. Duplicates from stage 3 samples (64 pairs; ~3%) yielded 100% concordance.
In technical validation, we observed a high correlation of genotyping calls from the OmniExpress microarray with confirmatory TaqMan assays in 455 stage 1 duplicate samples for 2 genotyped (rs13255292, r 2 = 1.00; rs4733601, r 2 = 1.00) and 4 imputed (rs116446171, r 2 = 0.92; rs2523607, r 2 = 0.99; rs2681416, r 2 = 1.00; rs79480871, r 2 = 0.94) SNPs. We also observed a high correlation of genotyping calls from the Illumina HumanHap660W microarray with confirmatory TaqMan assays in stage 2 duplicate samples from the Mayo study (n = 165) for 2 genotyped (rs13255292, r 2 = 1.00; rs4733601, r 2 = 1.00) and 4 imputed (rs116446171, r 2 = 1.00; rs2523607, r 2 = 1.00; rs79480871, r 2 = 0.85; rs79464052, r 2 = 0.95) SNPs. To assess imputation accuracy, we compared the imputed HLA alleles to HLA sequencing data (to four digits) available for a subset of samples from the NCI GWAS 14 and found high concordance rates for HLA-A (97.3%), HLA-B (98.5%), HLA-C (98.1%) and HLA-DRB1 (97.5%). Owing to the limited number of SNPs (n = 7,253) in the T1DGC reference set, imputation of HLA SNPs was conducted with IMPUTE2 and the 1000 Genomes Project reference set as described above. A total of 68,488 SNPs, 201 classical HLA alleles (at 2-and 4-digit resolution) and 1,038 AA markers, including 103 AA positions that were 'multiallelic' with 3 to 6 different residues present at each position, were successfully imputed (INFO score > 0.3 for SNPs or r 2 > 0.3 for alleles and AA markers) and available for analysis. Multiallelic markers were analyzed as binary markers (for example, having the allele present or absent) and using a global test, and a meta-analysis was conducted where we tested SNPs, HLA alleles and AA markers across the HLA region for association with DLBCL using PLINK 49 or SNPTEST as described above.
Expression quantitative trait locus analysis. To evaluate the effect of our top loci (and SNPs found to be in LD on the basis of r 2 > 0.8 in the HapMap CEU population, release 28) on gene expression, we conducted an eQTL analysis on lymphoblastoid cell lines using 2 independent data sets: childhood asthma 50 and HapMap 51 . For the childhood asthma data set 50 , peripheral blood lymphocytes were transformed into lymphoblastoid cell lines for 830 parents and offspring from 206 families of European ancestry. Using extracted RNA, gene expression was assessed with the Affymetrix HG-U133 Plus 2.0 chip. Genotyping was conducted using the Illumina Human1M BeadChip and Illumina HumanHap300K BeadChip, and imputation was performed using data from the 1000 Genomes Project. All SNPs selected for replication were tested for cis associations (defined as an effect on gene transcripts for genes npg within 1 Mb of the SNP), assuming an additive genetic model adjusted for non-genetic effects in the gene expression value. To gain insight into the relative importance of associations with our SNPs in comparison to other SNPs in the region, we also conducted conditional analyses in which both the DLBCL SNP and the most significant SNP for the particular gene transcript (peak SNP) were included in the same model. Only cis associations that reached P < 6.8 × 10 −5 , which corresponds to an FDR of 1%, are reported (Supplementary Table 10 ).
The HapMap data set consisted of a publicly available RNA sequencing data set 51 for transformed lymphoblastoid cell lines from 41 CEPH CEU individuals (HapMap), with samples available from the Gene Expression Omnibus (GEO) repository under accession GSE16921. Genotyping data for the same HapMap CEU individuals were directly downloaded from HapMap. Because rs2523607, rs79480871 and rs116446171 were not genotyped in HapMap, we selected rs3130923, rs6746301 and rs7762424 as respective proxies, as they were the most strongly linked SNPs available in HapMap (r 2 = 0.94, 0.69 and 0.54 in 1000 Genomes Project CEU data, respectively). Correlation between expression and genotype for each SNP-probe pair was tested using the Spearman's rank correlation test with t-distribution approximation and was estimated with respect to the minor allele in the HapMap CEU population. P values were adjusted using the Benjamini-Hochberg FDR correction, and eQTLs were considered significant at FDR ≤ 0.05 (Supplementary Table 11 ).
Bioinformatics: ENCODE and chromatin state dynamics. Using 1000 Genomes Project data, we identified SNPs with r 2 ≥ 0.8 with our sentinel SNPs that were reported to be nonsynonymous or nonsense variants. We used HaploReg v2 (ref. 15) , which is a tool for exploring noncoding functional annotation using ENCODE data, to evaluate the genome surrounding our SNPs (Supplementary Table 12 ). To assess chromatin state dynamics, we used ChroMoS 16 , which has precomputed data from ENCODE on nine cell types based on ChIP-seq analyses 17 . These precomputed data have genome segmentation performed using the multivariate hidden Markov model to reduce the combinatorial space to a set of interpretable chromatin states. The output from ChroMoS separates data into 15 chromatin states corresponding to repressed, poised and active promoters, strong and weak enhancers, putative insulators, transcribed regions and large-scale repressed and inactive domains (Supplementary Fig. 5 ).
Heritability analyses. To estimate the contribution of all common SNPs to the variance explained, we used the method proposed by Yang et al. 41 , which was extended to dichotomous traits 52 and implemented in Genome-Wide Complex Trait Analysis (GCTA) software 53 . The genetic similarity matrix was estimated from our stage 1 data using all genotyped autosomal SNPs with a MAF of >0.01. We used restricted maximum likelihood (REML), the default option for GCTA, to fit the appropriate variance components model that included the top ten eigenvectors as covariates. The final estimate of heritability on the underlying liability scale assumed that the lifetime risk of DLBCL was 0.0074 (ref. 54 ).
Estimate of recombination hotspots. To identify recombination hotspots in a region, we used SequenceLDhot 55 , a program that uses the approximate marginal likelihood method 56 and calculates likelihood ratio statistics at a set of possible hotspots. We tested 5 unique sets of 100 control samples. The PHASE v2.1 program was used to calculate background recombination rates 57, 58 , and LD heat maps were visualized in r 2 using the snp.plotter program 59 .
